Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 May 2025 | Story Martinette Brits | Photo Kaleidoscope Studios
Prof Hendrik Swart
Prof Hendrik Swart from the UFS Department of Physics was recently recognised by the Golden Key Honour Society Southern Africa as one of South Africa’s 300 most influential leaders.

Prof Hendrik Swart from the University of the Free State (UFS) Department of Physics was recently honoured at the Golden Key Honour Society Southern Africa’s Black Tie Gala Event, held on 23 May 2025. The event celebrated 300 of South Africa’s most influential leaders across academia, industry, government, and the financial sector.

Prof Swart, who is an NRF B1-rated researcher and currently also holds the SARChI Research Chair in Solid-state Luminescent and Advanced Materials (2023-2027), described the recognition as both meaningful and affirming at this stage of his academic journey.

“Being recognised by such a prestigious organisation is a meaningful acknowledgment of my academic efforts and personal dedication,” he says. “It was a moment of validation and inspiration, reminding me that hard work truly pays off.”

While the exact selection criteria were not publicly detailed, the emphasis was placed on academic excellence, scholarship, and leadership.

This is not Prof Swart’s first recognition from the Golden Key Honour Society. In 2012, the UFS student chapter awarded him honorary membership for his contributions as a mentor and supervisor – an early nod to his lasting impact on student success.

“The student chapter here on campus gave me some recognition by awarding me honorary membership,” he recalled. “It meant a lot to me as a mentor.”

The gala itself offered more than accolades – it created a space for meaningful exchange. Prof Swart reflected warmly on reconnecting with one of his former students from the early 2000s, calling it a highlight of the evening.

Looking ahead, Prof Swart welcomed the society’s plans to continue this initiative across the country.

“This was the first time they had an event like this, but more are expected to follow. I see it as a good initiative to mingle with other sectors in South Africa.”

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept